aminoflavone Prodrug (AFP-464) / Kirax - LARVOL DELTA

Systematic pan-cancer analysis identifies cGAS as an immunological and prognostic biomarker. (PubMed, Ann Transl Med) - "Finally, mithramycin, MI219, AFP464, aminoflavone, kahalide F, AT13387, doxorubicin, and other drugs increased the sensitivity of cGAS expression. This study discovered that SARS-CoV-2-infected cancer patients might experience changes in their tumor environment as a result of cGAS, making patients with tumors expressing high cGAS more susceptible to COVID-19 and possibly a worsening prognosis. Furthermore, cGAS may be a novel biomarker for diagnosing and treating COVID-19-infected tumor patients."

Biomarker • Journal • Pan tumor • Tumor mutational burden • Clear Cell Renal Cell Carcinoma • Gastrointestinal Cancer • Hepatology • Immune Modulation • Immunology • Infectious Disease • Inflammatory Arthritis • Lung Cancer • Novel Coronavirus Disease • Oncology • Pancreatic Cancer • Pneumonia • Renal Cell Carcinoma • Respiratory Diseases • Solid Tumor • CGAS • MSI • TMB

New Treatments in Renal Cancer: The AhR Ligands. (PubMed, Int J Mol Sci) - "Kidney cancer rapidly acquires resistance to antiangiogenic agents, such as sunitinib, developing an aggressive migratory phenotype (facilitated by c-Metsignal transduction)...Currently, there are two antitumor agent AhR ligands, with activity against renal cancer, that have been tested clinically: aminoflavone (AFP 464, NSC710464) and the benzothiazole (5F 203) prodrug Phortress...Current investigations are focused on the development of nano-delivery vehicles, apoferritin-encapsulated benzothiazoles 5F 203 and GW610, for the treatment of renal cancer. These compounds have shown improved antitumor effects against TK-10 cells in vitro at lower concentrations compared with a naked agent."

Journal • Review • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • AHR • MET